These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17676322)

  • 1. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
    Liljefors M; Nilsson B; Mellstedt H; Frödin JE
    Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
    Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
    Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
    Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.
    Ragnhammar P; Friesen HJ; Frödin JE; Lefvert AK; Hassan M; Osterborg A; Mellstedt H
    Blood; 1994 Dec; 84(12):4078-87. PubMed ID: 7994026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-macrophage colony-stimulating factor and interferon-alpha 2B in patients with advanced renal cell carcinoma.
    Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
    Urol Int; 1998; 61(4):215-9. PubMed ID: 10364752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
    Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H
    Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
    Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
    Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.
    Ragnhammar P; Frödin JE; Trotta PP; Mellstedt H
    Cancer Immunol Immunother; 1994 Oct; 39(4):254-62. PubMed ID: 7525059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor.
    Hovgaard D; Mortensen BT; Schifter S; Nissen NI
    Eur J Haematol; 1993 Jan; 50(1):32-6. PubMed ID: 8436212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
    Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
    Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
    Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
    Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
    J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer.
    Rucker R; Bresler HS; Heffelfinger M; Kim JA; Martin EW; Triozzi PL
    J Immunother; 1999 Jan; 22(1):80-4. PubMed ID: 9924703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
    O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
    Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor.
    Neidhart J; Allen KO; Barlow DL; Carpenter M; Shaw DR; Triozzi PL; Conry RM
    Vaccine; 2004 Jan; 22(5-6):773-80. PubMed ID: 14741172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.
    Baldwin GC; Chung GY; Kaslander C; Esmail T; Reisfeld RA; Golde DW
    Br J Haematol; 1993 Apr; 83(4):545-53. PubMed ID: 7686031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
    Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
    Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.